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BMI- Body mass index
CI- Confidence intervalCOPD- Chronic obstructive pulmonary disease
OR- Odds ratio(P < .001), and the median times from diagnosis were 27,
18.5, and 10 years, respectively. In males, the corresponding
remission rates were 36.7%, 20.0%, and 3.4%, and in fe-
males, 20.4%, 16.6%, and 5.9% (gender difference P < .001).
In multivariable binary logistic regression analysis, signifi-
cant risk factors of asthma nonremission were intermediate
(odds ratio [OR] [ 2.15, 95% confidence interval: 1.37-
3.36) and late diagnosis (OR[ 11.06, 4.82-25.37) compared
with early diagnosis, chronic obstructive pulmonary disease
(COPD) (OR [ 5.56, 1.26-24.49), allergic rhinitis (OR [
2.28, 1.50-3.46), and family history of asthma (OR [ 1.86,
1.22-2.85). Results were similar after excluding COPD.
CONCLUSION: Remission was rare in adults diagnosed with
asthma after age 40 years in both genders. Late-diagnosed
asthma was the most significant independent risk factor for
nonremission.  2020 The Authors. Published by Elsevier Inc.
on behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/). (J Allergy
Clin Immunol Pract 2021;9:1950-9)
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Asthma is a chronic respiratory disease with a tendency to vary
over time from more to less symptomatic periods and even
remission. Remission is most accurately defined as an asymp-
tomatic period of 12 months according to a recent consensus
report,1 and remitted asthma could also be considered as non-
active. Remission is noted as the most desirable, though difficult,
but increasingly achievable treatment goal in both children and
adults due to new treatment methods in asthma.1
A common symptom in children connected with childhood
asthma is wheezing, which diminishes in approximately 75% of
cases by mid-adulthood,2-5 and mostly already by age 12 years.6
Remission estimates in children vary noticeably by study
methods: only 20% of asthma, which was objectively confirmed
in early school-age remitted by age 19 years in Swedish data.7
Furthermore, one-third of males but only a minority of fe-
males with persistent medication-dependent asthma diagnosed
by age 19 years had remitted by 24 years of age in a recent
Finnish nation-wide register study.8 Severe asthma at baseline,
female gender, and allergic sensitization are most often reported
predictors of persistence of childhood asthma up to adult
age.2,3,5,7,9
In contrast to child-onset asthma, only 3% to 17% of adult-
onset asthma have remitted 5 to 25 years after the diagnosis.10-19
As well as being more frequently persistent,9 adult-onset asthma
is more often associated with faster loss of lung function and
poorer disease control than child-onset asthma.13,20,21 In adults
under 50 years of age, female gender, smoking, allergic sensiti-
zation, high body mass index (BMI), and increasing age are
commonly reported risk factors of nonremission or moreinadequate control of asthma symptoms, without specific
knowledge of asthma age of onset.11,12,22-24 In addition, it seems
that increasing age of onset would be a predisposing factor to
persistence also later in adulthood.14
However, studies evaluating asthma remission have rarely
been based on the general population or investigated remission
according to age of onset. Although child- and adult-onset
asthma have different characteristics,20,25,26 adult-onset asthma
is rarely divided and compared in early- and late-onset groups,
even though they seem to be distinct.27 Late-onset asthma (>40
years) has also been less studied. In addition, gender modifies
asthma incidence, persistence, and severity.7,8,22,23,28 Therefore,
this study aimed to evaluate the association between age at
asthma diagnosis, asthma remission, and gender, and to assess
diagnosis-age specific risk factors of nonremission in an adult
general population sample. We hypothesized that asthma diag-
nosed later in adulthood would be least often in remission, and
risk factors of nonremission would differ according to age at
diagnosis.
METHODS
Data acquisition and questionnaire
This study is a part of an international FinEsS (Finland, Estonia,
Sweden) study. Totally, 16,000 subjects aged 20 to 69 years, 8000
from Helsinki and 8000 from South Ostrobothnia and Vaasa areas
(Western Finland), were randomly selected by Statistics Finland in
10-year-age cohorts considering also gender distributions in the local
populations. Subjects were sent a FinEsS respiratory questionnaire in
February 2016, and in case of a nonresponse, up to 2 reminders were
sent. A more detailed description of the methods has been published
elsewhere.28,29 The flowchart of data conformation is shown in
Figure 1. Subjects with incomplete response to questions about
smoking habits were excluded.
Definitions of key parameters
The commonly used variables in this study were defined as
follows:
Physician-diagnosed asthma by the answer “yes” to the question
“Have you been diagnosed by a doctor as having asthma?”
Age at asthma diagnosis “What age were you when asthma was
diagnosed?”
Nonremitted asthma as physician-diagnosed asthma in combina-
tion with “yes” to at least 1 of the following questions: “Have you,
during the last 12 months, had asthma symptoms (intermittent at-
tacks or periodic breathlessness, with or without cough or wheezing/
whistling in your chest)?” OR “Have you had wheezing or whistling
in your chest at any time in the last 12 months?” OR “Do you
currently use asthma medication (regularly or as needed)?”
Remission of asthma in 12 months by reporting physician-
diagnosed asthma but not fulfilling criteria for nonremitted asthma.
Allergic rhinitis “Have you been diagnosed by a doctor as having
allergic rhinitis caused by pollen (caused by, eg, birch, grass, mug-
wort)?” OR “Have you been diagnosed by a doctor as having other
allergic rhinitis (caused by, eg, cat or dog)?”
Family history of asthma “Have any of your parents, brothers, or
sisters now or previously had asthma?”
Area of habitat by participation to either the Helsinki or Western
Finland sample.
COPD “Have you been diagnosed by a physician as having
chronic bronchitis, chronic obstructive pulmonary disease (COPD),
or emphysema?”
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or has there previously been a lot of dusts, gases, or fumes?”
Living in rural area in childhood “Did you live on the countryside
(not in a city or suburb) during your first 5 years of life?”
Living on a farm in childhood “Did you live on a farm during your
first 5 years of life?”
Exercise per week “Exercise on your free time: How often do you
exercise at least 30 minutes so that you are at least slightly short of
breath and get sweaty?”
Diagnosis-age specific variables were defined by reporting
physician-diagnosed asthma and concomitantly age at asthma diag-
nosis at:
0 to 11 years as early-diagnosed asthma,
12 to 69 years as adult-diagnosed asthma,
12 to 39 years as intermediate-diagnosed asthma, and
40 to 69 years of age as late-diagnosed asthma.
Remission was also evaluated in 10-year segments of diagnosis-
age.
Statistical analyses
Statistical analyses were conducted with IBM SPSS Statistics
version 25 (Armonk, NY). The c2 test was used in testing between
categorical variables. In testing between dichotomous categorical and
non-normally or normally distributed continuous variables, the
Mann-Whitney and t-test were used, respectively. In testing between
trichotomous categorical and non-normally or normally distributed
variables, the Kruskal-Wallis test and 1-way analysis of variance were
used, respectively. Normality in continuous variables was evaluated
by visual inspection of distribution. A P value of <.05 was
considered significant, and 95% confidence intervals (CIs) were
reported.
Multivariable binary logistic regression was used to determine
odds ratios (ORs) and CIs for asthma nonremission compared with
remission, and to simultaneously adjust for potential confounding
variables. Potential covariates were included in the model on the
grounds of knowledge from previous studies, clinical experience, and
significant association with the outcome variable. Covariates
included in the final model were age at asthma diagnosis, BMI, age,
gender, smoking, COPD, living in rural area in childhood, living on
a farm in childhood, exercise per week, occupational exposure,
allergic rhinitis, area of habitat, and family history of asthma. Re-
lationships of continuous time-measuring variables (age, age at
diagnosis, time from diagnosis) to asthma nonremission were
investigated each separately by univariate binary logistic regression,
to find out which of these variables had the strongest association
with nonremission. The ORs were reported in 10-year segments of
the time-measuring variables to clarify the result. Sensitivity analyses
were conducted by excluding coexisting COPD and altering the
remission definition by leaving out the criterion for asthma medi-
cation use.
RESULTS
Remission and age at diagnosis
Totally, 8199 subjects responded (51.5%). Basic responder
data and characteristics of subjects with a nonresponse are re-
ported elsewhere.28,29 Responders with incomplete smoking data
(N ¼ 269) were excluded (Figure 1). After exclusion, 879 of
7930 subjects (11.1%) reported physician-diagnosed asthma. In
162 (18.4%) subjects, asthma was in remission, and in 19.9% if
coexisting COPD was excluded. The median time from diag-
nosis was 19 years, and therefore the annual remission rate was0.97/100/year. Demographics of subjects with remitted and
nonremitted asthma are shown in Table I.
Age at asthma diagnosis was reported by 842 subjects with
physician-diagnosed asthma. Subjects with early-diagnosed (0-11
years) asthma had the lowest BMI, and they were most often
males and had most often allergic rhinitis as opposed to
intermediate-diagnosed (12-39 years) and late-diagnosed (40-69
years) asthma. In contrast, subjects with late-diagnosed asthma
had the highest BMI, they were mostly females, and only a third
of them had allergic rhinitis (Table II). Remission was most
common in early-diagnosed (30.2%), followed by intermediate-
diagnosed (17.9%), and least common in late-diagnosed asthma
(5.0%) (P < .001) (Figure 2, A). The median time from diag-
nosis was 27, 18.5, and 10 years, respectively, and the corre-
sponding remission rates were 1.12/100/year, 0.97/100/year,
and 0.50/100/year. If coexisting COPD was excluded, remission
rates were 30.8%, 18.8%, and 6.2%, respectively.
Remission was further assessed by dividing age at asthma
diagnosis into 10-year groups (Figure 2, B). A decrease in the
proportion of remitted subjects was seen by increasing age at
diagnosis: 22% to 29% of subjects with asthma diagnosed at 0 to
29 years of age were in remission, but if diagnosed at age 30 to
69 years, only 4% to 8% were in remission. When remission was
further assessed in 10-year groups by current age, subjects aged
30 to 39 years had the highest (28.5%) and those aged 60 to 69
years had the lowest (12.1%) proportion of remission (Figure E1,
available in this article’s Online Repository at www.jaci-
inpractice.org).
Risk factors of asthma nonremission
Adult-diagnosed (12-69 years) asthma (OR ¼ 2.97, CI: 2.06-
4.27) and both intermediate-diagnosed (12-39 years) (OR ¼
1.99, 1.35-2.92) and late-diagnosed (40-69 years) asthma
(OR ¼ 8.19, 4.31-15.55) (all P < .001) were significant risk
factors of nonremission in relation to early-diagnosed asthma in a
univariate binary logistic regression analysis. In addition, in 3
different univariate binary logistic regression analyses, the risk of
nonremission was most strongly increased by age at asthma
diagnosis (OR ¼ 1.45, P < .001, per 10-year increase) compared
with current age (OR ¼ 1.20, P ¼ .001, per 10-year increase) or
time from diagnosis (OR ¼ 1.33, P < .001, per 10-year
decrease).
To further investigate the risk factors of asthma nonremission,
we used multivariable binary logistic regression analysis, in which
statistically significant risk factors of nonremitted asthma were
intermediate or late diagnosis, coexisting COPD, allergic rhinitis,
and family history of asthma. Female sex and current smoking
showed tendency to increase risk of nonremission, and age,
occupational exposure, living in a rural area in childhood, living
on a farm in childhood, BMI, area of habitat, and exercise by
week were not significantly associated with nonremission
(Table III).
Independently analyzed, significant risk factors of non-
remission in subjects with early-diagnosed asthma (0-11 years)
were female gender and allergic rhinitis, and in adult-diagnosed
asthma (12-69 years), family history of asthma, late-diagnosed
asthma, and exercise 2 to 3 times per week, whereas coexisting
COPD showed a high effect size (OR ¼ 7.34) but was slightly
insignificant (P ¼ .055) probably due to insufficient data in the
subgroup (Table III). Furthermore, if the medication usage cri-
terion was left out of the definition of nonremission, and the
FIGURE 1. Flowchart of the study.
TABLE I. Demographics of subjects with physician-diagnosed asthma and comparison of remitted and nonremitted asthma
Variable
Physician-diagnosed asthma (N [ 879) Remitted asthma (N [ 162) Nonremitted asthma (N [ 717)
P#Median Q1-Q3 Median Q1-Q3 Median Q1-Q3
Age (y) 47 32-61 39 31-56 49 33-61 .001
Age at diagnosis (y)* 23 10-40 12 6-22 28 12-43 <.001
Time from diagnosis (y)* 19 10-28 23 17-23 18 8-26 <.001
Mean SD Mean SD Mean SD
BMI† 26.7 5.3 26.2 4.6 26.9 5.4 .15
N % N % N %
Female 498 56.7 72 44.4 426 59.4 .001
Family history of asthma 392 44.6 54 33.3 78 10.9 .001
Coexisting COPD 81 9.2 3 1.9 78 10.9 <.001
Smoking .16
Never 409 46.5 29 17.9 179 25.0
Current 208 23.7 53 32.7 209 29.1
Ex 262 29.8 80 49.4 329 45.9
Age at diagnosis (y)* <.001
0-11 245 29.1 74 49.3 171 24.7
12-39 358 42.5 64 42.7 294 42.5
40-69 239 28.4 12 8.0 227 32.8
Allergic rhinitis 508 57.8 84 51.9 424 59.1 .09
Living in rural area in
childhoodz
406 46.7 67 41.4 339 47.9 .13
Living on a farm in
childhoodx
233 27.0 36 22.2 197 28.1 .13
Exercise 2-3 times
per weekk
594 69.5 102 65.0 492 70.5 .16
Occupational exposure{ 335 39.3 49 31.0 286 41.2 .018
Helsinki as habitat 434 49.4 82 50.6 352 49.1 .73
BMI, Body mass index; COPD, chronic obstructive pulmonary disease; Q1-Q3, quartiles; SD, standard deviation.
Bolded text indicates statistical significance (P < .05).
Missing data: *37, †13, z10, x15, k24, {27.
#Measured by the c2 test in categorical variables, by the Mann-Whitney test in non-normally distributed continuous variables, and by the t-test in BMI.
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risk factor of nonremission, whereas other significant associations
remained (Table E1, available in this article’s Online Repository
at www.jaci-inpractice.org).A similar regression analysis was also conducted separately for
intermediate- (12-39 years) and late-diagnosed (40-69 years)
asthma. The only significant risk factor of nonremission in
intermediate-diagnosed asthma (N ¼ 328 in regression) was
TABLE II. Demographics and comparison of subjects with physician-diagnosed asthma categorized by age at asthma diagnosis
Variable
Early-diagnosed
asthma (0-11 y) (N [ 245)
Intermediate-diagnosed
asthma (12-39 y) (N [ 358)
Late-diagnosed
asthma (40-69 years) (N [ 239)
P#Median Q1-Q3 Median Q1-Q3 Median Q1-Q3
Age (y) 32 26-44 42 32-54 62 57-66 <.001
Time from diagnosis (y)* 27 20-39 19 10-28 10 4-17 <.001
Mean SD Mean SD Mean SD
BMI† 25.6 4.8 26.5 5.2 28.1 5.4 <.001
N % N % N %
Female 98 40.0 223 62.3 152 63.6 <.001
Family history of asthma 112 45.7 159 44.4 104 43.5 .89
Coexisting COPD 8 3.3 28 7.8 44 18.4 <.001
Smoking .002
Never 124 50.6 172 48.0 98 41.0
Current 68 27.8 80 22.3 49 20.5
Ex 53 21.6 106 29.6 92 38.5
Allergic rhinitis 174 71.0 228 63.7 85 35.6 <.001
Living in rural area in
childhoodz
99 40.4 155 43.8 139 59.7 <.001
Living on a farm in
childhoodx
43 17.6 75 21.3 108 46.8 <.001
Exercise 2-3 times
per weekk
165 67.9 248 71.5 160 69.6 .64
Occupational exposure{ 76 31.5 125 36.1 117 51.3 <.001
Helsinki as habitat 131 53.5 184 51.4 100 41.8 .022
BMI, Body mass index; COPD, chronic obstructive pulmonary disease; Q1-Q3, quartiles; SD, standard deviation.
Bolded text indicates statistical significance (P < .05).
Missing data: *37, †13, z10, x15, k24, {27.
#Measured by the c2 test in categorical variables, by the Kruskal-Wallis test in non-normally distributed continuous variables, and by 1-way analysis of variance in BMI.
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.013). Because the number of subjects in remission was very low
in late-diagnosed asthma, risk factors of nonremission could not
be reliably assessed. However, all the subjects who had coexisting
COPD were not in remission.
As subjects with coexisting COPD were excluded to investi-
gate its possible confounding effect, current smoking (OR ¼
1.84, 1.05-3.23, P ¼ .033) became an additional significant risk
factor of nonremission in physician-diagnosed asthma in similar
regression analysis as in Table III (Table E2, available in this
article’s Online Repository at www.jaci-inpractice.org). The re-
sults remained mainly similar also regarding risk factors of adult-
diagnosed asthma nonremission. In addition, if time from
diagnosis was included as an additional covariate to the regression
model, the association with late-diagnosed asthma remained
statistically significant (Table E3, available in this article’s Online
Repository at www.jaci-inpractice.org).
Remission and gender
Based on previous knowledge of gender differences in asthma
and a significant association between gender and asthma remis-
sion in this study, gender-specific remission was assessed. Of
males, 23.6%, and of females, 14.5% were in remission (P ¼
.001). Males and females in remission versus nonremission had
lower age at asthma diagnosis, less often coexisting COPD and
occupational exposure. Furthermore, males in remission versus
nonremission were younger and had less often a family history of
asthma (Table IV).Males with early-diagnosed asthma were more frequently in
remission than females (P < .006), but no significant difference
was found in remission of intermediate- or late-diagnosed asthma
between genders (Figure 3, A). Furthermore, when investigated
in 10-year groups, a trend of decreasing remission by increasing
diagnosis-age was seen in both genders (Figure 3, B). As diag-
nosed at 0 to 29 years of age, asthma was in remission in 27% to
35% and 20% to 23% of males and females, respectively. In
contrast, if diagnosis was made in 30 to 69 years of age, corre-
sponding percentages were 0% to 12% and 5% to 7%.
DISCUSSION
The primary result of this study was that remission of asthma
became rarer as the age at diagnosis of asthma increased. The
finding remained similar after adjusting by multiple confounding
variables. Furthermore, age at diagnosis pooled in 10-year groups
showed that any asthma diagnosed after age 30 years was prone
not to be in remission in both genders.
The annual remission rate was 0.97/100/year in all subjects
with physician-diagnosed asthma, 1.12/100/year in early-
diagnosed, 0.97/100/year in intermediate-diagnosed, and 0.50/
100/year in late-diagnosed asthma. The overall annual remission
rate was similar to earlier reports,11,17 but diagnosis-age centered
remission rates have not been assessed previously, to the best of
our knowledge. The cut-points of the diagnosis-age groups were
chosen mainly based on asthma incidence switches28 and cut-
points used in the existing literature.25 Particularly, age 40
years as a cut-point for adult-onset asthma has also been
FIGURE 2. Remission (%) in subjects with physician-diagnosed asthma in groups defined by age at asthma diagnosis. In (A) is shown the
proportion of remission in subjects with early (0-11), intermediate (12-39 years) and late-diagnosed (40-69 years) asthma. In (B) is shown
the proportion of remission in subjects divided into 10-year groups by age at asthma diagnosis.
TABLE III. Risk factors of asthma nonremission compared with remission in subjects with physician-diagnosed asthma, and separately in
subjects with early-diagnosed (0-11 years) and adult-diagnosed (12-69 years) asthma in multivariable binary logistic regression analysis*
Variable
Physician-diagnosed
asthma (N [ 773)
Early-diagnosed
asthma (0-11 y) (N [ 234)
Adult-diagnosed
asthma (12-69 y) (N [ 539)
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Female 1.47 (0.96-2.25) .07 2.39 (1.17-4.87) .017 1.07 (0.60-1.90) .82
Family history of asthma 1.86 (1.22-2.85) .004 1.77 (0.89-3.51) .10 1.78 (1.00-3.16) .050
Smoking
Never 1 1 1
Current 1.66 (0.96-2.87) .068 1.48 (0.66-3.36) .34 1.94 (0.85-4.43) .11
Ex 0.99 (0.61-1.60) .97 0.93 (0.40-2.14) .86 1.19 (0.64-2.19) .58
Occupational exposure 1.30 (0.83-2.04) .26 1.43 (0.68-2.98) .35 1.30 (0.71-2.38) .39
Living in rural area in childhood 1.19 (0.69-2.05) .52 1.46 (0.60-3.56) .41 0.91 (0.44-1.87) .79
Living on a farm in childhood 0.80 (0.44-1.46) .47 0.85 (0.29-2.50) .77 0.83 (0.39-1.78) .64
BMI
<24.99 1 1 1
25-29.99 1.00 (0.62-1.60) .99 0.84 (0.39-1.82) .66 1.07 (0.57-2.03) .83
30-34.99 0.92 (0.52-1.63) .77 0.85 (0.34-2.15) .74 0.92 (0.42-1.98) .82
>35 1.84 (0.58-5.87) .30 1.42 (0.18-11.48) .74 2.30 (0.49-10.68) .29
Age at diagnosis (y) N/D
0-11 1
12-39 2.15 (1.37-3.37) .001 1
40-69 11.08 (4.82-25.45) <.001 5.04 (2.17-11.71) <.001
Exercise 2-3 times per week 1.34 (0.87-2.07) .18 0.64 (0.31-1.30) .22 2.16 (1.20-3.87) .010
Allergic rhinitis 2.29 (1.50-3.47) <.001 4.89 (2.44-9.80) <.001 1.58 (0.89-2.80) .12
Age (y)
60-69 1 1 1
50-59 1.40 (0.66-2.97) .38 0.58 (0.13-2.59) .48 1.86 (0.74-4.72) .19
40-49 1.11 (0.54-2.31) .78 0.81 (0.19-3.53) .78 1.03 (0.42-2.48) .96
30-39 0.97 (0.48-1.96) .94 0.40 (0.11-1.49) .17 1.34 (0.54-3.29) .53
20-29 1.58 (0.75-3.31) .23 0.78 (0.22-2.82) .71 1.81 (0.63-5.17) .27
Coexisting COPD 5.56 (1.26-24.51) .023 1.66 (0.15-17.85) .68 7.34 (0.96-56.19) .055
Helsinki as habitat 0.98 (0.62-1.55) .92 1.01 (0.48-2.15) .97 0.99 (0.54-1.83) .98
BMI, Body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.
Bolded text indicates statistical significance (P < .05).
*Three different multiple logistic regression analyses were conducted with a target variable of remission of asthma. Nonremission was coded as 1 and remission as 0. Reported
ORs have been adjusted for all the variables listed.
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asthma (N [ 381)
Remitted
asthma (N [ 90)
Nonremitted
asthma (N [ 291)
P#
Physician-diagnosed
asthma (N [ 498)
Remitted
asthma (N [ 72)
Nonremitted
asthma (N [ 426)
P#Median (Q1-Q3) Median (Q1-Q3) Median (Q1-Q3) Median (Q1-Q3) Median (Q1-Q3) Median (Q1-Q3)
Age (y) 44 (32-59) 36 (29-52) 46 (33-60) .004 49 (33-61) 45 (32-59) 51 (33-62) .09
Age at diagnosis (y)* 18 (6-35) 9 (5-19) 21 (8-40) <.001 28 (14-43) 17 (10-25) 30 (15-45) <.001
Time from diagnosis (y)* 20 (11-29) 24 (18-27) 18 (10-27) <.001 18 (8-27) 23 (15-33) 17 (7-26) .001
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
BMI† 27.1 (5.0) 26.6 (4.8) 27.2 (5.0) .37 26.5 (5.5) 25.6 (4.4) 26.7 (5.6) .15
N (%) N (%) N (%) N (%) N (%) N (%)
Family history of asthma 154 (40.4) 25 (27.8) 129 (44.3) .005 238 (47.8) 29 (40.3) 209 (49.1) .17
Coexisting COPD 42 (11.0) 2 (2.2) 40 (13.7) .002 39 (7.8) 1 (1.4) 38 (8.9) .028
Smoking .36 .21
Never 147 (38.6) 38 (42.2) 109 (37.5) 262 (52.6) 42 (58.3) 220 (51.6)
Current 107 (28.1) 20 (22.2) 87 (29.9) 101 (20.3) 9 (12.5) 92 (21.6)
Ex 127 (33.3) 32 (35.6) 95 (32.6) 135 (27.1) 21 (29.2) 114 (26.8)
Age at diagnosis (y)* <.001 .002
0-11 147 (39.8) 54 (64.3) 93 (32.6) 98 (20.7) 20 (30.3) 78 (19.2)
12-39 135 (36.6) 27 (32.1) 108 (37.9) 223 (47.1) 37 (56.1) 186 (45.7)
40-69 87 (23.6) 3 (3.6) 84 (29.5) 152 (32.1) 9 (13.6) 143 (35.1)
Allergic rhinitis 219 (57.5) 48 (53.3) 171 (58.8) .36 289 (58.0) 36 (50.0) 253 (59.4) .14
Living in rural area in
childhoodz
168 (44.7) 36 (40.0) 132 (46.2) .31 238 (48.3) 31 (43.1) 207 (49.2) .34
Living on a farm in
childhoodx
100 (26.6) 21 (23.3) 79 (27.6) .42 133 (27.3) 15 (20.8) 118 (28.4) .19
Exercise 2-3 times
per weekk
236 (63.6) 54 (60.7) 182 (64.5) .51 358 (74.0) 48 (70.6) 310 (74.5) .49
Occupational exposure{ 190 (51.5) 36 (41.4) 154 (54.6) .031 145 (30.0) 13 (18.3) 132 (32.0) .020
Helsinki as habitat 189 (49.6) 43 (47.8) 146 (50.2) .69 245 (49.2) 39 (54.2) 206 (48.4) .36
BMI, Body mass index; COPD, chronic obstructive pulmonary disease; Q1-Q3, quartiles; SD, standard deviation.
Bolded text indicates statistical significance (P < .05).
Missing in males: *12, †3, z5, x5, k10, {12. Missing in females: *25, †10, z5, x10, k14, {15.






































FIGURE 3. Gender-specific remission (%) in subjects with physician-diagnosed asthma in groups defined by age at asthma diagnosis. In
(A) is shown the proportion of remission in subjects with early (0-11), intermediate (12-39 years) and late-diagnosed (40-69 years)
asthma. In (B) is shown the proportion of remission in subjects divided into 10-year groups by age at asthma diagnosis.
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to a recent consensus report that argued 12 months to be the
most optimal asymptomatic time frame to the definition of
asthma remission.1
Early-diagnosed asthma (<12 years) was in remission in 30%
of subjects: in 37% of males and 20% of females. Child-onset
asthma is mostly defined similarly, as beginning at <12 years
of age in other studies comparing asthma by age of onset.25 Our
remission estimates were low compared with studies with a
symptom-based definition of asthma,3 but very similar to studies
that have included only physician-diagnosed or objectively
confirmed asthma.7,8 In addition, we found 2 risk factors of
nonremission in early-diagnosed asthma: allergic rhinitis and
female gender, similarly as in earlier reports.3,7,9
Intermediate-diagnosed asthma (12-39 years) was in remission
in 17.9% of subjects, which settles between earlier findings.11,30
The diagnosis-age definition in this group reflects quite well
those of adult-onset or late-onset asthma in previous studies
comparing asthma by age of onset because older subjects have
been left out in most of them.25,30 Interestingly, exercise 2 to 3
times per week was the only significant risk factor of non-
remission in this group, which however lost its significance if
subjects reporting current asthma medication use but not
symptoms were considered as remitted. This suggests preventa-
tive medication usage in exercising subjects to explain the result.
Other studies have similarly found only few risk factors of
nonremission in subjects with similar diagnosis age: nasal polyps,
allergic sensitization, worse lung function at baseline, inhaled
corticosteroid use.10,11,17,30 Daily physical activity has also been
found to decelerate the loss of lung function in the long term in
adult-onset asthma.31
Only 5% of subjects with late-diagnosed asthma were
currently in remission. The result is in line with a previous
prospective case-control study that reported remission rate by
detailed diagnosis age in older age.11 Our study was under-
powered to determine risk factors of nonremitted late-diagnosed
asthma, but all the subjects who had coexisting COPD were not
in remission. Furthermore, remission was rarest in subjects aged
60 to 69 years, which could result from a higher proportion of
worse-prognostic adult-diagnosed asthma in those with older age,
but also from an increase in other comorbid conditions associ-
ated with age, which may play a role in asthma control.32,33Comorbid COPD is reportedly a predisposing factor to poorer
lung function in asthma,34,35 but other comorbidities are also
found to be more prevalent in patients with coexisting asthma
and COPD than other patients with asthma.34 Nevertheless, to
the best of our knowledge, this was the first study to investigate
risk factors of asthma nonremission by detailed asthma age of
onset in adulthood and one of the few studies to investigate
remission of asthma in the elderly population.
The 2 most remarkable independent risk factors of asthma
nonremission were late-diagnosed asthma (OR ¼ 11.1) and
coexisting COPD (OR ¼ 5.6). Exclusion of coexisting COPD
did not affect the effect size or significance of late diagnosis (40-
69 years) as a risk factor for nonremission, supporting its role as a
real-life independent risk factor. Support for late diagnosis as a
COPD-independent risk factor for poorer asthma prognosis is
also provided in another study.35 However, the effect size of late
diagnosis age as a risk factor of asthma nonremission in an
extensive stratified regression model has not been described
earlier, to the best of our knowledge.
Current smoking transformed into a significant risk factor of
asthma nonremission as subjects with coexisting COPD were
excluded. Current smoking and smoking history are both indeed
found to increase the risk of at least more difficult asthma.36,37
Furthermore, BMI was not a significant risk factor of non-
remission in any diagnosis-age group. High BMI was previously
found to increase risk of more difficult asthma in a “dose-
response” manner,38 but another study, which also found an
association between high BMI and more difficult asthma,
showed that BMI and the actual remission of asthma were not
associated,11 consistent with this study.
In general, retrospective studies have limitations. Under-
reporting mild asthma due to recall bias is found to be com-
mon39 as well as misdiagnosis of asthma.40 However, in Finland,
the standard practice is to confirm asthma and COPD diagnoses
with objective lung function tests highly recommended by
Global Initiative for Asthma and the Finnish national health care
guidelines, increasing the reliability of asthma diagnoses.41,42 In
addition, all citizens in Finland are covered by the National
Health Insurance scheme and issued a personal health insurance
card. This card is replaced usually 6 to 8 months from asthma
diagnosis, containing not only asthma medication reimburse-
ment information but also the replacement date. The card is
J ALLERGY CLIN IMMUNOL PRACT
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proportion of the respondents had verified data of their age at
asthma diagnosis at hand when they filled the questionnaire. In
addition, reimbursement of asthma medication8 contributes a
notable financial benefit to patients, which further enhances the
memory related to precise diagnosis age, which was asked the
study subjects with a well-validated questionnaire.28
Furthermore, in this study, a risk of misinterpretation of early-
diagnosed asthma to adult-diagnosed asthma is present43 as child-
onset asthma may relapse after a long remission period in mid-
adulthood.4,5 However, subjects diagnosed in childhood are
mostly allergic andmales, whereas adult-diagnosed subjects mostly
nonallergic and females,20,28 therefore having different permanent
characteristics. This also applied to our findings, suggesting that
misinterpretation of early-onset relapsed asthma to adult-
diagnosed asthma would not have caused a major bias. On the
other hand, retrospective self-reported asthma age of onset
assessment is previously found to be very specific.39,44 For these
reasons, we consider the reported asthma diagnoses in the present
study to be precise and comprehensive, and only little misclassi-
fication of early-diagnosed asthma to late-diagnosed asthma or
asthma to COPD in the older age groups. Therefore, although
some mild asthma is probably left out, overall, we consider the
reported asthma diagnoses in this study to be accurate.
Our data were based on an age-comprehensive cross-sectional
random sample of general adult population: subjects were invited
to the study with no exclusions, and all subjects who filled the
questionnaire appropriately were included. In addition, the effect
of nonresponse is previously discussed to be moderate in this
study.28,29 It should also be noted that cohort effect affects the
results, as the oldest subjects had lived their childhood a long
time ago, when asthma incidence was lower and identification
more difficult. However, similar data would be very troublesome
to collect prospectively. Furthermore, the data were based solely
on the questionnaire, and clinical parameters were not available.
Therefore, the evidence of distinguishing nonremitted and
remitted asthma was not as accurate as in clinical data. However,
clinical data are usually collected from secondary health care.
Thus, we consider the results from these data accurate and
generalizable to the primary health care patients as subjects
conformed the general population.
As discussed, remission of asthma was lowest in subjects with
later diagnosis age as has been reported earlier,45 and the finding
was parallel in both genders. In addition, it is shown that in adult
subjects, current adult-onset asthma is more common than
current child-onset asthma8,28 and that adult-onset asthma pre-
disposes to poorer response to traditional asthma medications,
and uncontrolled asthma,20 the mechanism being still un-
known.32,33 Taking all these findings into account, adult-onset
asthma contributes a marked burden to the health care system
altogether. What is also notable is that age of onset had the
strongest association with asthma remission of the time-
measuring variables in this study, which implicates that it
would be a better factor to characterize asthma remission ten-
dency than the age or duration of asthma of patients. In
conclusion, to affect prognosis of asthma, follow-up resources
should be increased in adult-onset asthma, and follow-up needs
to be intensified especially in patients whose asthma has occurred
after 30 years of age as they have the highest risk of
nonremittance.In conclusion, age at asthma diagnosis predicted well the
probability of asthma remission through the age span. Adult-
diagnosed asthma was rarely in remission, and even less often
with increasing age at diagnosis. Gender did not seem to have a
significant impact on remission of asthma diagnosed in adult-
hood. Age at diagnosis also defined the risk factors of non-
remission, suggesting distinct differences between these
phenotypes. More resources to adult-onset and especially late-
onset adult asthma should be targeted, in terms of follow-up as
well as in research, especially to unravel novel targets for more
effective prevention or treatment methods.Acknowledgments
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As similar regression analysis with a similar definition of
nonremission as in Table E1 was conducted separately for
intermediate- (12-39 years) and late-diagnosed (40-69 years)
asthma, no significant risk factors of nonremission wereFIGURE E1. Remission (%) in subjects with physician-diagnosed asth
from diagnosis in 10-year categories.found in intermediate-diagnosed (12-39 years) asthma.
Because the number of subjects in remission was very low in
late-diagnosed asthma, risk factors of nonremission could
not be reliably assessed.ma in relation to age at asthma diagnosis, current age, and time
TABLE E1. Risk factors of asthma nonremission compared with remission in subjects reporting physician-diagnosed asthma and separately in subjects with early-diagnosed (0-11 years)
and adult-diagnosed (12-69 years) asthma in multivariable binary logistic regression analysis as the criterion of reporting not using asthma medication was removed from the definition of
asthma remission*
Variable
Physician-diagnosed asthma (N [ 773) Early-diagnosed asthma (0-11 y) (N [ 234) Adult-diagnosed asthma (12-69 y) (N [ 539)
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Female 1.20 (0.84-1.71) .32 2.01 (1.05-3.86) .035 0.94 (0.60-1.47) .78
Family history of asthma 1.74 (1.23-2.46) .002 1.64 (0.87-3.08) .13 1.69 (1.10-2.61) .017
Smoking
Never 1 1 1
Current 1.36 (0.86-2.13) .19 1.07 (0.51-2.25) .87 1.52 (0.82-1.81) .18
Ex 0.87 (0.59-1.30) .50 0.93 (0.42-2.05) .86 0.87 (0.54-1.39) .55
Occupational exposure 1.46 (1.01-2.12) .046 1.83 (0.92-3.67) .09 1.38 (0.88-2.18) .16
Living in rural area in childhood 1.28 (0.82-2.00) .28 1.42 (0.63-3.21) .39 1.19 (0.68-2.08) .55
Living on a farm in childhood 0.90 (0.55-1.48) .68 0.85 (0.32-2.27) .74 0.96 (0.52-1.75) .88
BMI
<24.99 1 1 1
25-29.99 1.26 (0.85-1.87) .25 1.11 (0.54-2.29) .78 1.32 (0.81-2.13) .27
30-34.99 1.44 (0.88-2.37) .15 0.94 (0.40-2.21) .88 1.72 (0.91-3.25) .10
>35 2.32 (0.96-5.59) .062 2.17 (0.30-15.89) .45 2.63 (0.95-7.30) .064
Age at diagnosis (y) N/D
0-11 1
12-39 1.63 (1.09-2.43) .017 1
40-69 3.41 (1.85-6.27) <.001 2.06 (1.15-3.69) .016
Exercise 2-3 times per week 1.02 (0.71-1.49) .91 0.56 (0.29-1.09) .09 1.34 (0.84-2.15) .22
Allergic rhinitis 1.69 (1.19-2.42) .004 3.50 (1.80-6.82) <.001 1.35 (0.87-2.10) .22
Age (y)
60-69 1 1 1
50-59 1.36 (0.76-2.42) .30 0.54 (0.13-2.33) .41 1.64 (0.86-3.15) .14
40-49 1.04 (0.57-1.89) .91 0.45 (0.11-1.80) .26 1.12 (0.56-2.26) .75
30-39 0.99 (0.54-1.78) .96 0.41 (0.12-1.46) .17 1.12 (0.55-2.31) .75
20-29 1.65 (0.88-3.11) .12 0.71 (0.21-2.45) .59 1.85 (0.79-4.37) .16
Coexisting COPD 2.18 (0.98-4.85) .057 2.51 (0.26-24.23) .43 1.96 (0.83-4.63) .12
Helsinki as habitat 1.04 (0.71-1.51) .86 1.29 (0.64-2.59) .48 1.00 (0.62-1.59) .99
BMI, Body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.
Bolded text indicates statistical significance (P < .05).
















































TABLE E2. Risk factors of asthma nonremission compared with remission in subjects with physician-diagnosed asthma and adult-
diagnosed (12-69 years) asthma in multivariable binary logistic regression analysis as coexisting COPD was excluded*
Variable
Physician-diagnosed asthma, COPD
excluded (N [ 707)
Adult-diagnosed asthma (12-69 y), COPD
excluded (N [ 481)
OR (95% CI) P OR (95% CI) P
Female 1.41 (0.92-2.16) .12 1.02 (0.57-1.82) .96
Family history of asthma 1.93 (1.26-2.96) .003 1.74 (0.98-3.10) .060
Smoking .033 .07
Never 1 .95 1 .62
Current 1.84 (1.05-3.23) 2.20 (0.94-5.19)
Ex 0.98 (0.61-1.59) 1.17 (0.63-2.16)
Occupational exposure 1.20 (0.76-1.89) .43 1.20 (0.65-2.19) .56
Living in rural area in childhood 1.26 (0.72-2.18) .42 0.98 (0.47-2.05) .95
Living on a farm in childhood 0.77 (0.42-1.41) .40 0.77 (0.36-1.67) .51
BMI .87 .98
<24.99 1 .61 1 .66
25-29.99 0.96 (0.60-1.55) .35 1.01 (0.53-1.91) .36
30-34.99 0.86 (0.48-1.53) 0.84 (0.39-1.82)
>35 1.74 (0.54-5.62) 2.05 (0.44-9.57)
Age at diagnosis (y) .001 <.001
0-11 1 <.001
12-39 2.20 (1.40-3.46) 1
40-69 11.48 (4.93-26.72) 4.87 (2.07-11.43)
Exercise 2-3 times per week 1.34 (0.86-2.07) .19 2.03 (1.13-3.67) .019
Allergic rhinitis 2.34 (1.53-3.57) <.001 1.54 (0.86-2.75) .15
Age (y)
60-69 1 1
50-59 1.55 (0.72-3.35) .27 2.12 (0.81-5.56) .13
40-49 1.12 (0.54-2.35) .76 0.99 (0.41-2.41) .98
30-39 0.98 (0.48-1.99) .95 1.28 (0.52-3.17) .60
20-29 1.68 (0.79-3.57) .17 1.75 (0.61-5.04) .30
Helsinki as habitat 0.96 (0.60-1.53) .85 0.93 (0.50-1.73) .82
BMI, Body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.
Bolded text indicates statistical significance (P < .05).
*Two different multiple logistic regression analyses were conducted with a target variable of remission of asthma. Nonremission was coded as 1 and remission as 0. Reported
ORs have been adjusted for all the variables listed.
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TABLE E3. Risk factors of asthma nonremission compared with remission in subjects with physician-diagnosed asthma in multivariable
binary logistic regression analysis as time from diagnosis variable was included, and in addition as coexisting COPD was excluded*
Variable
Physician-diagnosed asthma (N [ 773) Physician-diagnosed asthma, COPD excluded (N [ 707)
OR (95% CI) P OR (95% CI) P
Female 1.47 (0.96-2.24) .077 1.41 (0.92-2.16) .12
Family history of asthma 1.88 (1.23-2.87) .004 1.95 (1.27-3.00) .002
Smoking
Never 1 1
Current 1.68 (0.97-2.90) .066 1.85 (1.05-3.26) .033
Ex 0.99 (0.62-1.61) .98 0.99 (0.61-1.60) .95
Occupational exposure 1.28 (0.81-2.01) .29 1.18 (0.75-1.87) .47
Living in rural area in childhood 1.17 (0.68-2.02) .57 1.23 (0.71-2.15) .46
Living on a farm in childhood 0.80 (0.44-1.45) .46 0.76 (0.42-1.40) .38
BMI
<24.99 1 1
25-29.99 1.02 (0.63-1.64) .95 0.98 (0.60-1.58) .92
30-34.99 0.91 (0.51-1.62) .75 0.86 (0.48-1.53) .61
>35 1.84 (0.58-5.87) .30 1.73 (0.54-5.58) .36
Age at diagnosis (y)
0-11 1 1
12-39 1.67 (1.00-2.81) .052 1.77 (1.05-3.00) .033
40-69 6.23 (2.25-17.29) <.001 7.04 (2.49-19.87) <.001
Time from asthma diagnosis (y)
20 1 1
10-19 1.21 (0.69-2.13) .51 1.11 (0.63-1.97) .71
0-9 2.29 (1.04-5.04) .039 2.10 (0.95-4.63) .067
Exercise 2-3 times per week 1.40 (0.91-2.17) .13 1.38 (0.89-2.15) .15
Allergic rhinitis 2.38 (1.56-3.63) <.001 2.42 (1.58-3.71) <.001
Age (y)
60-69 1 1
50-59 1.27 (0.59-2.73) .54 1.43 (0.65-3.12) .38
40-49 0.92 (0.43-1.97) .84 0.96 (0.44-2.06) .91
30-39 0.76 (0.35-1.62) .47 0.79 (0.37-1.70) .55
20-29 1.05 (0.42-2.61) .91 1.21 (0.48-3.06) .68
Coexisting COPD 5.35 (1.22-23.48) .026 N/D
Helsinki as habitat 0.99 (0.62-1.57) .95 0.97 (0.60-1.55) .89
BMI, Body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.
Bolded text indicates statistical significance (P < .05).
*Two different multiple logistic regression analyses were conducted with a target variable of remission of asthma. Nonremission was coded as 1 and remission as 0. Reported
ORs have been adjusted for all the variables listed.
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